IDH1 and IDH2 mutations are detected in approximately 60%‐80% and 1%‐5% of patients with WHO grades II‐III astrocytoma or oligodendroglioma and are predominantly IDH1 p.R132H (>90%).8 Here, IDH1 is linked to astrocytoma (excluding glioblastoma).